Higher extracellular volume (ECV ≥32.3%) combined with significant valvular disease predicted major adverse cardiac events with a hazard ratio of 2.91 in DCM and HFrEF patients.
Does the combination of high extracellular volume fraction on CT and significant valvular disease on TTE predict MACE in patients with DCM and HFrEF?
101 consecutive patients with dilated cardiomyopathy (DCM) and heart failure with reduced ejection fraction (HFrEF, LVEF < 40%) who underwent cardiac CT and TTE.
Combination of extracellular volume fraction (ECV) ≥32.3% on cardiac CT and presence of moderate or severe valvular disease on TTE
Patients with only one of these factors (ECV ≥32.3% or significant valvular disease) or neither factor
Major adverse cardiac events (MACE)composite
The combination of elevated extracellular volume on cardiac CT and significant valvular disease on echocardiography strongly predicts major adverse cardiac events in patients with dilated cardiomyopathy and HFrEF.
Abstract Introduction Transthoracic echocardiography (TTE) is a traditional examination to evaluate cardiac function, such as ejection fraction or the presence of valvular disease. Cardiac computed tomography (CT) helps screen coronary artery stenosis in cases with dilated cardiomyopathy (DCM). Extracellular volume fraction (ECV) analysis has recently been eligible for CT (Figure A), and it is known as a new parameter of myocardial fibrosis. Purpose The purpose of this study is to evaluate the influence of the combination of ECV of LVM on CT and the presence of significant valvular disease on the patient’s prognosis in DCM. Methods We analyzed 101 consecutive DCM cases with heart failure with reduced ejection fraction (HFrEF) who underwent cardiac CT and TTE. All patients had a lower left ventricular (LV) ejection fraction (LVEF) of less than 40% on TTE. Results Major adverse cardiac events (MACE) occurred in 27 cases (27%). The patients with MACEs had a higher prevalence of moderate or severe valvular disease on TTE (52% vs. 19%, P = 0.0011) and an increased ECV on LVM on CT (37.2 ± 6.7 vs. 32.2 ± 3.6%, P = 0.0008) compared to the others (74 cases). Based on the receiver operating characteristics curve analysis, the best cutoff value of ECV on LVM to predict MACE was 32.3%. All patients were classified into 3 groups; 26 patients with ECV ≥32.3 and significant valvular disease, 39 patients with ECV ≥32.3 or significant valvular disease, and 36 patients had neither ECV ≥32.3 nor significant valvular disease. In each group, 14 of 26 patients (53.9%), 11 of 39 patients (28.2%), 2 of 36 patients (5.6%) had MACE (p0.01). Based on the Kaplan-Meier analysis, the patients with ECV ≥32.3% and significant valvular disease had significantly higher MACE compared to other groups (p=0.002) (Figure B). ECV ≥32.3 and significant valvular disease was the significant predictor of MACE based on the univariate Cox proportional hazard model (Hazard ratio 2.91, 95% confidence interval 1.35 – 6.26, P = 0.0062). Conclusion The combination of higher ECV of LVM on CT and the presence of significant valvular disease helps predict MACE in cases with DCM and HFrEF.
Building similarity graph...
Analyzing shared references across papers
Loading...
Kazuo Watanabe
H Takaoka
M Matsumoto
European Heart Journal
Chiba University
Teikyo University Chiba Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Watanabe et al. (Sat,) reported a other. Higher extracellular volume (ECV ≥32.3%) combined with significant valvular disease predicted major adverse cardiac events with a hazard ratio of 2.91 in DCM and HFrEF patients.
www.synapsesocial.com/papers/698586498f7c464f2300a491 — DOI: https://doi.org/10.1093/eurheartj/ehaf784.352